
    
      OBJECTIVES:

        -  Determine the safety and efficacy of forodesine (BCX-1777) in patients with refractory
           stage IIA-IVB cutaneous T-cell lymphoma.

        -  Determine the pharmacokinetics and pharmacodynamics of this drug in these patients.

      OUTLINE: This is an open-label, multicenter study.

      Patients receive oral forodesine (BCX-1777) once daily on days 1-28. Courses may be repeated
      in the absence of disease progression or unacceptable toxicity.

      Patients are followed periodically.

      PROJECTED ACCRUAL: Not specified.
    
  